Cancer Family
Hematopoietic and Lymphatic System Neoplasm
CI-CAN-00000022Explore in graph →
Non-malignant4,304 active trials98 approved drugs1,010 evidence items
- NCIt
- C35813
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000022Explore in graph →
Clinical trials
18,827 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01219816 | Multi-centric Study(CHEPRALL) | completed | Phase 2 | 57 | Nantes University HospitalOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT01279694 | Trial of Carfilzomib Plus Melphalan and Prednisone in Elderly Untreated Patients With Multiple Myeloma (CARMYSAP)(CARMYSAP) | completed | Phase 1 / Phase 2 | 72 | Nantes University HospitalOTHER | 1 | Sep 14, 2026 |
| NCT01309334 | Imaging Young Myeloma (IMAgerie JEune Myélome)(IMAJEM) | completed | Phase 3 | 152 | Nantes University HospitalOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT01541280 | VIDAZA-DLI Pre-emptive Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome(VIDAZA-DLI) | completed | Phase 2 | 30 | Nantes University HospitalOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT01572181 | Study of a Reduced-toxicity Myeloablative Conditioning Regimen Using Fludarabine and Full Doses of Intravenous Busulfan in Pediatric Patients Not Eligible for Standard Myeloablative Conditioning Regimens(FB4-PEDIA) | completed | Phase 2 | 50 | Nantes University HospitalOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT01936532 | Safety and Efficacy Study of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone in the Initial Management of Multiple Myeloma (IFM2013-06)(IFM2013-06) | completed | Phase 2 | 42 | Nantes University HospitalOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT01971658 | Efficacy Study Comparing Velcade Dexamethasone Thalidomide Versus Velcade Cyclophosphamide Dexamethasone as Induction Treatment in the Initial Management of Multiple Myeloma (IFM2013-04)(IFM2013-04) | completed | Phase 3 | 358 | Nantes University HospitalOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT02180724 | An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia | active not recruiting | Phase 2 | 107 | Acerta Pharma BVINDUSTRY | 7 | Sep 14, 2026 | clinicaltrials |
| NCT02464696 | Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure | recruiting | N/A | 256 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT02530463 | Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome | active not recruiting | Phase 2 | 99 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT02558816 | A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients(OAsIs) | completed | Phase 1 / Phase 2 | 48 | Nantes University HospitalOTHER | 2 | Sep 14, 2026 | clinicaltrials |
| NCT02689440 | Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia | active not recruiting | Phase 2 | 155 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT03267433 | Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission | active not recruiting | Phase 3 | 689 | ECOG-ACRIN Cancer Research GroupNETWORK | 2 | Sep 14, 2026 | clinicaltrials |
| NCT03471260 | Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies | recruiting | Phase 1 / Phase 2 | 96 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT03683433 | Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation | recruiting | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04075292 | Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia | active not recruiting | Phase 3 | 155 | AstraZenecaINDUSTRY | 5 | Sep 14, 2026 | clinicaltrials |
| NCT04115631 | A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma | active not recruiting | Phase 2 | 360 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04128501 | Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting | active not recruiting | Phase 2 | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04216524 | Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm | recruiting | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04246086 | A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma | active not recruiting | Phase 1 / Phase 2 | 237 | Hoffmann-La RocheINDUSTRY | 5 | Sep 14, 2026 | clinicaltrials |
| NCT04270266 | Mind-Body Medicine for the Improvement of Quality of Life in Adolescents and Young Adults Coping With Lymphoma | active not recruiting | N/A | 71 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04314752 | Development of a Research Infrastructure for Understanding and Addressing Multiple Myeloma Disparities(MEDULLA) | recruiting | — | 4,000 | University of California, DavisOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04544592 | UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL | recruiting | Phase 1 / Phase 2 | 45 | University of Colorado, DenverOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04547062 | Monocentric Phase 1 Study With Escalation of Doses of Tocilizumab in Combination With Chemotherapy (Idarubicin and Cytarabine) in Patients With Acute Myeloblastic Leukemia (AML)(Tocilam) | completed | Phase 1 | 12 | Nantes University HospitalOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04649073 | Safety and Efficacy Study of OPC-415 in Patients With Relapsed and/or Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 11 | Otsuka Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04771130 | A Study of BGB-11417 in Participants With Myeloid Malignancies | recruiting | Phase 1 / Phase 2 | 260 | BeOne MedicinesINDUSTRY | 10 | Sep 14, 2026 | clinicaltrials |
| NCT04984551 | Impact of Project ECHO on Improving the Quality of Palliative Care in Patients With Advanced Cancer and Their Caregivers in Underserved Areas of Kenya, Nigeria, Ghana, South Africa, India, and Ethiopia | recruiting | Phase 2 | 312 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04993690 | A Study of LP-168 in Participants With Relapse or Refractory B-Cell Lymphoma | recruiting | Phase 1 | 200 | Guangzhou Lupeng Pharmaceutical Company LTD.INDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05691608 | MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2(MAPPYACTS2) | recruiting | N/A | 1,800 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06090539 | A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas | recruiting | Phase 1 / Phase 2 | 460 | Bristol-Myers SquibbINDUSTRY | 15 | Sep 14, 2026 | clinicaltrials |
| NCT06137144 | AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.(PRIMAVERA) | recruiting | Phase 1 / Phase 2 | 161 | AstraZenecaINDUSTRY | 11 | Sep 14, 2026 | clinicaltrials |
| NCT06192875 | A Novel Molecular Approach to Blood DNA Screening for Cancer: Specificity Assessment (The NOMAD Study) | recruiting | — | 10,000 | Mayo ClinicOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06241729 | Prospective Observational Study of Diffuse Large-cell B Lymphoma(LBDGCréfract) | recruiting | — | 50 | Grand Hôpital de CharleroiOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06242834 | Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma | active not recruiting | Phase 2 | 11 | Northwestern UniversityOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06297226 | Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma(QUINTESSENTIAL) | recruiting | Phase 2 | 230 | Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyINDUSTRY | 4 | Sep 14, 2026 | clinicaltrials |
| NCT06514508 | Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients | recruiting | Phase 3 | 60 | Guangzhou Gloria Biosciences Co., Ltd.INDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06724237 | Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy | recruiting | Phase 3 | 294 | Eastern Cooperative Oncology GroupNETWORK | 2 | Sep 14, 2026 | clinicaltrials |
| NCT06765876 | CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Dose Escalation Phase I Trial(UHKT-CAR123-01) | active not recruiting | Early Phase 1 | 18 | Institute of Hematology and Blood Transfusion, Czech RepublicOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06827860 | Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse | recruiting | Phase 2 | 23 | Larysa SanchezOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06846606 | Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS | recruiting | Phase 1 | 69 | Auron Therapeutics, Inc.INDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06953960 | A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM) | recruiting | Phase 1 / Phase 2 | 325 | AbbVieINDUSTRY | 12 | Sep 14, 2026 | clinicaltrials |
| NCT07003100 | A Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or Sezary Syndrome and Treated With Standard of Care Mogamulizumab | recruiting | — | 100 | City of Hope Medical CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07085728 | Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure | recruiting | Phase 2 | 74 | Eastern Cooperative Oncology GroupNETWORK | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07168486 | CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas | enrolling by invitation | Phase 1 | 15 | University of Maryland, BaltimoreOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07178912 | Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL) | not yet recruiting | Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07285668 | Prophylactic TCRaB+ and CD19+ Depleted Donor Lymphocyte Infusion After Allogeneic Stem Cell Transplant in High-Risk Patients With Hematologic Malignancies | recruiting | N/A | 38 | University of Wisconsin, MadisonOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07313592 | Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients | suspended | — | 60 | Washington University School of MedicineOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07558915 | A Study to Evaluate RO7851624 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) | recruiting | Phase 1 | 160 | Genentech, Inc.INDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07731789 | Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma | not yet recruiting | Phase 2 | 30 | University of WashingtonOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT07739459 | Study of Zanubrutinib in Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)(ZEN-CLL) | not yet recruiting | Phase 2 | 95 | The Lymphoma Academic Research OrganisationOTHER | 1 | Sep 14, 2026 | clinicaltrials |
Data updated 16 days agoSource updated Sep 14, 2026source: clinicaltrials